Table 1 Baseline characteristics (n=32)
From: Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
Age (years) | 82.0 ± 6.3 |
Male/Female | 20/12 |
BMI (kg/cm2) | 22.0 ± 3.3 |
Systolic Diastolic BP (mmHg) | 122.6 ± 20.2 |
Diastolic BP (mmHg) | 59.5 ± 11.2 |
EF (%) | |
HFrEF -no.(%) | 5 (16) |
HFmrEF -no.(%) | 4 (13) |
HFpEF -no.(%) | 23 (72) |
Laboratory data | |
Albumin (g/dl) | 3.7 ± 0.5 |
BUN (mg/dl) | 31.6 ± 11.9 |
Cre (mg/dl) | 1.6 ± 0.6 |
eGFR (mL/min/1.73m2) | 32.6 ± 11.6 |
Na (mEql/l) | 138.7 ± 3.9 |
K (mEql/l) | 4.4 ± 0.5 |
Cl (mEql/l) | 103.7 ± 3.8 |
RBC (× 104/mm3) | 336.1 ± 59.1 |
Hb (g/dl) | 10.1 ± 1.4 |
Hct (%) | 31.2 ± 4.5 |
MCV (fl) | 94.9 ± 7.9 |
Reticulo (× 104/μl) | 4.7 ± 1.4 |
Plt (× 104/mm3) | 17.7 ± 7.3 |
Fe (μg/dl) | 67.3 ± 24.3 |
TSAT (%) | 24.2 ± 10.0 |
Ferritin (ng/ml) | 149.8 ± 158.5 |
CRP | 0.9 ± 2.5 |
NT-proBNP (pg/ml) | 1177 (642–1840) |